Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380294 | 1.00 | ALDH1A1 (0.57) | ALDH1A1DRD2DRD3MAPKAPK2SLC6A9 | |
| Hydrochloric Acid SCHEMBL22532864 | 0.98 | ALDH1A1 (0.56) | ALDH1A1DRD2DRD3MAPKAPK2SLC6A9 | |
| Hydrochloric Acid SCHEMBL29380273 | 0.98 | ALDH1A1 (0.56) | ALDH1A1DRD2DRD3MAPKAPK2SLC6A9 | |
| Hydrochloric Acid SCHEMBL29882265 | 0.98 | ALDH1A1 (0.56) | ALDH1A1DRD2DRD3MAPKAPK2SLC6A9 | |
| SCHEMBL25629584 | 0.94 | ALDH1A1 (0.52) | ALDH1A1DRD2DRD3MAPKAPK2SLC6A9 | |
| Hydrochloric Acid SCHEMBL31720538 | 0.93 | ALDH1A1 (0.51) | ALDH1A1DRD2DRD3MAPKAPK2SLC6A9 | |
| SCHEMBL3164773 | 0.87 | ALDH1A1 (0.57) | ALDH1A1DRD2DRD3MAPKAPK2HTR6 | |
| Hydrochloric Acid SCHEMBL23303687 | 0.85 | ALDH1A1 (0.56) | ALDH1A1DRD2DRD3MAPKAPK2HTR6 | |
| SCHEMBL15117102 | 0.85 | SLC6A9 (0.57) | ALDH1A1SLC6A9ADRA1DADRA1AADRA1B | |
| SCHEMBL8415671 | 0.82 | SLC6A9 (0.46) | ALDH1A1SLC6A9ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4467143-A2 | 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE AS ANTIPROLIFERATIVE COMPOUND | Celgene Corporation (US) | 2024-11-27 | — | — | EP | claimed |
| US-12029738-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2024-07-09 | — | — | US | claimed |
| US-20220280505-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2022-09-08 | — | — | US | claimed |
| US-10675281-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2020-06-09 | — | — | US | claimed |
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725553-A2 | SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260001863-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | CELGENE CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3908582-B1 | SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2025-11-12 | — | — | EP | disclosed |
| US-6630475-B2 | 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine adenosine A2a receptor antagonists; use in the treatment of central nervous system diseases, in particular Parkinson's disease | SCHERING CORPORATION | 2003-10-07 | — | — | US | disclosed |
| EP-1283839-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-07-25 | — | — | US | disclosed |
| WO-2001092264-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6013654-A | Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases | PHARMACIA & UPJOHN COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-5912246-A | Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0809642-A1 | IMIDAZO 1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025414-A1 | IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SUCNR1, SRD5A1, GLS | ALDH1A1 697/4885DRD2 4186/4885DRD3 3575/4885 |
| US-12029738-B2 | Antiproliferative compounds and methods of use thereof | MCL1, NPM1, NFATC1 | ALDH1A1 2344/4885DRD2 4810/4885DRD3 4675/4885 |
| US-10675281-B2 | Antiproliferative compounds and methods of use thereof | MCL1, NPM1, NFATC1 | ALDH1A1 2344/4885DRD2 4810/4885DRD3 4675/4885 |
| US-20260001863-A1 | NOVEL PYRIDAZINES | ENPP2, LPAR5, LPAR1 | ALDH1A1 2616/4885DRD2 2576/4885DRD3 3251/4885 |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | IKZF1, IKZF3, IKZF2 | ALDH1A1 3404/4885DRD2 4207/4885DRD3 3122/4885 |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | ALDH1A1 2158/4885DRD2 75/4885DRD3 123/4885 |
| US-20220280505-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, NPM1, NFATC1 | ALDH1A1 2344/4885DRD2 4810/4885DRD3 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.